SequelSEC

Traws Pharma, Inc. TRAW

Pharmaceutical Preparations · CIK 0001130598 · Fiscal year ends 1231

Revenue
$2.79M
Fiscal year ended 2025-12-31
Operating income
-$17.88M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$9.80MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.65Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income1.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue3.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Net margin328.7%99th
Revenue YoY growth1134.5%96th
Current ratio0.72x12th
Operating margin-640.7%38th
SBC / revenue26.1%52th

Traws Pharma, Inc. (TRAW) reported revenue of $2.79M and net income of $9.17M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Traws Pharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Traws Pharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$2.79M$226.00K$226.00K$226.00K$226.00K$231.00K$2.18M$1.23M$787.00K$5.55M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$17.88M-$142.37M-$20.30M-$19.63M-$16.50M-$24.99M-$21.70M-$23.28M-$25.74M-$23.70M
Net income$9.17M-$166.52M-$18.95M-$18.96M-$16.16M-$25.16M-$21.50M-$20.57M-$24.09M-$19.67M
Research & developmentUnavailableUnavailable$11.43M$11.41M$7.30M$16.90M$15.54M$16.92M$19.12M$20.07M
Weighted-average diluted sharesshares 8.38Mshares 1.55MUnavailableshares 20.91Mshares 16.83Mshares 11.60MUnavailableUnavailableUnavailableUnavailable
Pretax income$9.17M-$166.53M-$18.95M-$18.96M-$16.16M-$25.15M-$21.49M-$20.53M-$24.08M-$19.65M
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailable$4.00K$10.00K-$124.00K$13.00K$14.00K
Diluted EPS$0.82$-35.21$-22.57$-0.91$-0.96$-2.17UnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$8.52M$12.29M$9.09M$8.45M$9.42M$8.33M$8.34M$7.59M$7.40M$9.18M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Traws Pharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalentsUnavailableUnavailable$20.56M$38.52MUnavailableUnavailableUnavailableUnavailableUnavailable$21.40M
Total assets$10.62M$24.96M$22.68M$39.37M$55.48M$19.99M$23.67M$17.92M$4.98M$23.23M
Current assets$7.98M$24.95M$22.66M$39.35M$55.43M$19.78M$23.47M$17.76M$4.90M$23.07M
Total liabilities$11.25M$56.59M$12.01M$11.06M$9.36M$13.81M$12.10M$12.54M$15.84M$18.11M
Current liabilities$11.15M$11.53M$9.22M$8.05M$6.12M$10.02M$8.29M$8.44M$9.98M$10.16M
Total equity incl. NCI-$629.00K-$31.63M$10.67M$28.31M$46.12M$6.18M$11.57M$5.39M-$10.86M$5.13M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$3.79M$1.76M$18.00K$29.00K$28.00K$37.00K$98.00K$35.00K$59.00K$31.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$5.65M$8.19M$5.62M$3.86M$2.76M$4.83M$4.27M$4.04M$6.19M$5.32M

Cash flow

Traws Pharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$18.18M-$29.79M-$17.93M-$16.29M-$19.49M-$23.08M-$20.83M-$22.70M-$23.82M-$15.81M
Capital expendituresUnavailableUnavailable$14.00KUnavailableUnavailable$15.00K$55.00KUnavailableUnavailableUnavailable
Investing cash flow-$2.58M-$3.65M-$14.00KUnavailableUnavailable-$15.00K-$55.00KUnavailableUnavailableUnavailable
Financing cash flow$3.20M$33.98MUnavailableUnavailable$55.56M$19.36M$26.65M$35.66M$6.36M$17.42M
Net change in cash-$17.52M$517.00K-$17.94M-$16.31M$36.04M-$3.70M$5.76M$12.95M-$17.43M$1.60M
Stock-based compensation$728.00K$1.39M$1.30M$1.17M$576.00K$369.00K$1.05M$1.15M$1.71M$3.93M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$61.00K$12.00K$16.00K$14.00K$14.00K$13.00K$14.00K$55.00K$88.00K$96.00K

Derived

Traws Pharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flowUnavailableUnavailable-$17.95MUnavailableUnavailable-$23.09M-$20.89MUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-640.7%-62997.3%-8981.4%-8684.5%-7299.1%-10819.5%-994.0%-1895.9%-3270.3%-427.4%
FCF marginUnavailableUnavailable-7940.7%UnavailableUnavailable-9995.7%-956.8%UnavailableUnavailableUnavailable
SBC / revenue26.1%615.0%575.7%518.6%254.9%159.7%48.0%93.4%217.3%70.8%
Current ratio0.72x2.16x2.46x4.89x9.06x1.97x2.83x2.11x0.49x2.27x
Revenue YoY growth1134.5%0.0%0.0%0.0%-2.2%-89.4%77.8%56.0%-85.8%Unavailable
Net margin328.7%-73682.7%-8384.1%-8391.2%-7151.8%-10890.5%-985.0%-1675.3%-3061.2%-354.6%
R&D / revenueUnavailableUnavailableUnavailable5046.9%3228.8%7315.2%711.7%1378.2%2429.4%361.9%
CapEx / revenueUnavailableUnavailable6.2%UnavailableUnavailable6.5%2.5%UnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TRAW in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.